Phase II trial of thalidomide for patients with advanced renal cell carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Kidney

abstract

  • This trial does not support the routine use of thalidomide to induce partial response for metastatic RCC. Because disease stabilization occurs as a part of the natural history of metastatic RCC, the potential effect of thalidomide on progression-free and overall survival for patients with advanced RCC is being addressed in a randomized phase III trial. New immunomodulatory analogs of thalidomide that have shown potentially greater antitumor effects in preclinical models warrant study in metastatic RCC.

publication date

  • January 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1200/JCO.20.1.302

PubMed ID

  • 11773183

Additional Document Info

start page

  • 302

end page

  • 6

volume

  • 20

number

  • 1